Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Helsinn Healthcare, a drug development company, and Zealand Pharma have signed a partnering agreement for the development and worldwide commercialization of Zealand's ZP1846, a glucagon-like peptide-2 receptor agonist, which is reported to provide a novel way to treat chemotherapy-induced diarrhea, a debilitating condition affecting patients undergoing cancer treatment with a range of chemotherapies.
Subscribe to our email newsletter
Under the terms of the agreement, Helsinn Healthcare will receive a worldwide exclusive license to ZP1846 and will be responsible for all further development, regulatory approvals, manufacturing, marketing and sales of the compound either on its own or through its sub-licensees.
In return, Helsinn Healthcare will pay Zealand Pharma development milestones and sales milestones for an undisclosed amount. In addition, Zealand Pharma will receive royalties on future sales and Zealand Pharma retains the marketing rights to the Nordic countries. The total value of the non-royalty portion of the partnership is valued at E140 million.
Riccardo Braglia, Helsinn Healthcare’s CEO, said: We are excited about this promising development and commercial co-operation with Zealand Pharma, which represents another important step in broadening and strengthening Helsinn Healthcare’s pipeline of cancer supportive care products.
We are confident that ZP1846 will be an important contribution to the treatment of chemotherapy-induced diarrhea, currently an unmet medical need and consequently, a positive impact on patients’ quality of life.